这是演示店铺,请务下单付款,避免造成你的财物损失。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

Tocilizumab (anti-IL-6R)

功能和特点
  • 规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
  • 应用: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
  • 反应种属: Cynomolgus,Human
  • 亚型: Human IgG1
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
T412004-1mg
1mg 期货 Stock Image
T412004-5mg
5mg 期货 Stock Image
T412004-10mg
10mg 期货 Stock Image
查看相关系列
Interleukin-6 receptor Antibody

基本信息

产品名称 Tocilizumab (anti-IL-6R)
别名 托珠单抗; Tocilizumab (anti-IL-6R); Recombinant Tocilizumab Antibody; Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab); MRA; Anti-Human IL6R; Humanized Antibody; Tocilizumab; CD 126 antibody; CD126 antibody; CD126 antigen antibody; Gp80 antibody; IL 6R 1
英文别名 Tocilizumab (anti-IL-6R); Recombinant Tocilizumab Antibody; Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab); MRA; Anti-Human IL6R; Humanized Antibody; Tocilizumab; CD 126 antibody; CD126 antibody; CD126 antigen antibody; Gp80 antibody; IL 6R 1 antibo
规格或纯度 Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性 IL-6Ra/CD126
应用 ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属 Cynomolgus,Human

产品属性

抗体类型 Primary antibody
Format Whole IgG
亚型 Human IgG1
轻链亚型 Kappa
SDS-PAGE 26.6 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 174.3 kDa, under non-reducing conditions.
纯化方法 Protein A purified
来源 CHO supernatant
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 Lot by Lot
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息 375823-41-9

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J et al..  (2006)  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate..  Arthritis Rheum,  54  (9):  (2817-29).  [PMID:16947782]
2. Paul-Pletzer K.  (2006)  Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders..  Drugs Today,  42  (9):  (559-76).  [PMID:17028666]
3. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.  (2007)  Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease..  Intern Med,  46  (11):  (771-4).  [PMID:17541233]
4. Nishimoto N, Kishimoto T.  (2008)  Humanized antihuman IL-6 receptor antibody, tocilizumab..  Handb Exp Pharmacol,  71  (181):  (151-60).  [PMID:18071945]
5. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y.  (2005)  Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family..  Int Immunopharmacol,  (12):  (1731-40).  [PMID:16102523]
6. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M.  (2005)  Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis..  Clin Rev Allergy Immunol,  28  (3):  (231-8).  [PMID:16129907]
7. Ohsugi Y, Kishimoto T.  (2008)  The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis..  Expert Opin Biol Ther,  (5):  (669-81).  [PMID:18407769]
8. Unizony S, Kermani TA.  (2018)  IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis..  J Neuroophthalmol,  38  (4):  (551-558).  [PMID:30199509]
9. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J et al..  (2021)  Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19..  JAMA Intern Med,  181  (1):  (41-51).  [PMID:33080002]
10. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C et al..  (2021)  Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial..  JAMA Intern Med,  181  (1):  (24-31).  [PMID:33080005]
11. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, CORIMUNO-19 Collaborative Group.  (2021)  Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial..  JAMA Intern Med,  181  (1):  (32-40).  [PMID:33080017]
12. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM et al..  (2020)  Efficacy of Tocilizumab in Patients Hospitalized with Covid-19..  N Engl J Med,  383  (24):  (2333-2344).  [PMID:33085857]
13. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B et al..  (2020)  Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019..  Clin Infect Dis,  71  (8):  (1937-1942).  [PMID:32301997]
14. Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, Lie P, Huang L, Cheng L, Lin Y et al..  (2020)  Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics..  J Infect Dis,  222  (9):  (1444-1451).  [PMID:32601708]

计算器